INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENTInvestigator Initiated Clinical Trial Agreement • October 21st, 2019 • Kazia Therapeutics LTD • Pharmaceutical preparations • Massachusetts
This Investigator Initiated Clinical Trial Agreement (“Agreement”) is made as of the _I7* day of October. 20LS (“Effective Date”) between Kazia Therapeutics Ltd (ACN 063 259 754) a company incorporated in Australia with a principal place of business at 1.24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Company”), and Dana-Farber/Partners Cancer Care, Inc., a collaboration among Dana-Farber Cancer Institute, The Brigham and Women’s Hospital, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts with its principal place of business at 44 Binney Street, Boston, MA 02115 (“Institution”) each referred to herein individually as a “Party” and collectively as the “Parties”.
INVESTIGATOR INITIATED CLINICAL TRIAL AGREEMENTInvestigator Initiated Clinical Trial Agreement • October 22nd, 2020 • Kazia Therapeutics LTD • Pharmaceutical preparations • Massachusetts
This Investigator Initiated Clinical Trial Agreement (“Agreement”) is made as of the 18th September 2020 (“Effective Date”) between Kazia Therapeutics Limited (ACN 063 259 754) a company incorporated in Australia with a principal place of business at L24, 300 Barangaroo Avenue, Sydney, NSW 2000, Australia (“Company”), and Dana-Farber/Partners Cancer Care, Inc., a collaboration among Dana-Farber Cancer Institute, The Brigham and Women’s Hospital, Inc. and The General Hospital Corporation, d/b/a Massachusetts General Hospital, a not-for-profit tax-exempt corporation organized under the laws of the Commonwealth of Massachusetts with its principal place of business at 450 Brookline Ave., Boston, MA 02215 (“Institution”) each referred to herein individually as a “Party” and collectively as the “Parties”.
INVESTIGATOR INITIATED-CLINICAL TRIAL AGREEMENTInvestigator Initiated-Clinical Trial Agreement • May 26th, 2021 • XORTX Therapeutics Inc. • Pharmaceutical preparations • New York
This Investigator-Initiated Clinical Trial Agreement ("Agreement") effective this 3rd day of August, 2020, (the "Effective Date") is by and between ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, a non-profit corporation, having its principal offices at One Gustave L. Levy Place, New York, NY 10029 ("INSTITUTION") and XORTXTherapeutics ("COMPANY"), a Canadian corporation, having its principal offices at Suite 4000, 421-7th Avenue Calgary, Alberta, Canada. INSTITUTION's faculty employee Steven Coca, M.D. ("PRINCIPAL INVESTIGATOR") shall be the Sponsor-Investigator under this Agreement, and shall conduct this Study as an employee of lnstitution and not as a party to this Agreement.
